Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,498,720
  • Shares Outstanding, K 64,600
  • Annual Sales, $ 1,280 K
  • Annual Income, $ -173,140 K
  • 36-Month Beta 2.13
  • Price/Sales 52.17
  • Price/Cash Flow N/A
  • Price/Book 30.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.85 +31.37%
on 01/02/18
23.90 -1.88%
on 01/22/18
+5.10 (+27.79%)
since 12/22/17
3-Month
14.40 +62.85%
on 10/25/17
23.90 -1.88%
on 01/22/18
+7.95 (+51.29%)
since 10/20/17
52-Week
12.25 +91.43%
on 01/30/17
23.90 -1.88%
on 01/22/18
+10.15 (+76.32%)
since 01/20/17

Most Recent Stories

More News
Options Traders Expect Huge Moves in Heron Therapeutics (HRTX) Stock

Investors in Heron Therapeutics (HRTX) need to pay close attention to the stock based on moves in the options market lately.

HRTX : 23.45 (+1.08%)
Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises

--- 2018 Net Sales Guidance for CINV Franchise of $60 Million to $70 Million -

HRTX : 23.45 (+1.08%)
Heron Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient...

JPM : 114.33 (+1.17%)
HRTX : 23.45 (+1.08%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Heron Therapeuti (HRTX, INSY, VTL, ONCE, ESPR)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ESPR : 77.93 (+0.95%)
ONCE : 57.35 (+11.88%)
INSY : 9.59 (+10.36%)
HRTX : 23.45 (+1.08%)
VTL : 6.00 (+9.09%)
Heron Therapeutics Announces Pricing of Public Offering of Common Stock

Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the...

HRTX : 23.45 (+1.08%)
Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on NVS, HRTX, AERI, and PFE which is a click away at www.wallstequities.com/registration....

AERI : 59.95 (+1.10%)
NVS : 87.00 (+0.07%)
PFE : 36.93 (-0.03%)
HRTX : 23.45 (+1.08%)
Recent Analysis Shows Premier, Quantum, Heron Therapeutics, Dillard's, LightPath Technologies, and Ichor Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Premier, Inc. (NASDAQ:PINC),...

DDS : 70.65 (+0.70%)
ICHR : 34.02 (+5.03%)
PINC : 32.55 (-0.21%)
QTM : 6.33 (-1.09%)
LPTH : 2.60 (+7.44%)
HRTX : 23.45 (+1.08%)
Heron Therapeutics Announces U.S. FDA Approval of CINVANTI(TM) (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)

--- Heron's CINV Franchise Is the Only Franchise to Include Approved Injectable Therapies That Address Both Mechanisms of CINV -

HRTX : 23.45 (+1.08%)
Heron Therapeutics to Present at the Jefferies London Healthcare Conference

Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient...

HRTX : 23.45 (+1.08%)
Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress

Heron Therapeutics, Inc. (Nasdaq:HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important...

HRTX : 23.45 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

2nd Resistance Point 24.23
1st Resistance Point 23.84
Last Price 23.45
1st Support Level 23.12
2nd Support Level 22.78

See More

52-Week High 23.90
Last Price 23.45
Fibonacci 61.8% 19.45
Fibonacci 50% 18.08
Fibonacci 38.2% 16.70
52-Week Low 12.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.